drug
golimumab
Marketedupdated 3mo agoby Janssen Biotech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3indications
investigational
IBD (Crohn's + UC)Rheumatoid Arthritis
all catalysts(0)
nothing on the calendar yet
Trials studying golimumab
- phase3A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
- phase2Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
- phase2A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
- phase2A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
- phase2A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
- phase3GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA
- phase3A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
- phase3A Study of Golimumab in Participants With Active Ankylosing Spondylitis
News(3)
- Avalo shares spike on skin drug data; BioNTech to cut staffAvalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.biopharma_dive · 3mo ago
- STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and moreHHS Secretary Robert F. Kennedy Jr. announced initiatives to rein in prescribing of SSRIs, the most widely used antidepressantsstat · 3mo ago
- STAT+: Johnson & Johnson advances IBD therapy, despite trial missA closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.stat · 3mo ago
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that